Navigation Links
MIGENIX Corporate Update and Requisition of Special Meeting
Date:7/8/2008

s after approval of the product. This is a significant value opportunity for MIGENIX and was made possible only through the perseverance and commitment of the current management team and board of directors. Those knowledgeable about the biotech industry and the product development process understand that clinical success is required for value creation in drug development companies. We are no exception and have confidence in our strategy and in our ability to continue following through with the value opportunities we have created, regardless of the challenges inherent in this industry."

Program Update

Management and the Board have built a solid portfolio (pipeline) of programs to maximize value potential and mitigate development risk. The status of these programs is as follows:

Omigard(TM) (1% topical omiganan pentahydrocloride for preventing catheter-related infections): Patient enrolment in the Phase III US and European registration clinical trial conducted by Cadence Pharmaceuticals (who is fully funding the Omigard development program) is complete (see May 6, 2008 press release). Cadence expects to announce top-line data from this trial in the second half of 2008 and, with positive results, submit a new drug application for Omigard(TM) to the FDA in the first half of 2009. Upon successful completion of various milestones in this program (starting with FDA acceptance of the NDA for filing), we can receive up to US$27MM in development and commercialization milestone payments and a double-digit royalty on net sales. Cadence's commercialization focus is on the United States market and thus Cadence intends to establish a strategic partnership(s) for the commercialization of Omigard(TM) for the rights it has outside of the United States. MIGENIX management and Board are working to out-license Omigard(TM) rights either in combination with Cadence's rights outside the US to prospective global partners or to potential regional partners for rest of wor
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Deadly viruses such as Ebola are the target ... University City Science Center's Port business incubator at ... $4.5 million Phase 2 SBIR grant from the National ... is focused on therapies for unmet medical needs while ... first-in-class protease inhibitors based on a technology platform inspired ...
(Date:4/27/2015)... , April 27, 2015 SynGen Inc., ... of instrument systems that harvest stem and progenitor cells ... cell culture, announced today that it has added three ... Processing and Cord Blood Business Units focus on product ... management team as its Vice President and Chief Financial ...
(Date:4/27/2015)... CHARLESTON, W.Va. , April 27, 2015 /PRNewswire/ ... Company which operates lawsuitsettlementnews.com, reports today that U.S. ... court order for another joint conference status meeting ... mesh lawsuits against seven different mesh manufacturers who ... TVM multidistrict litigations (MDL) have been going on ...
(Date:4/27/2015)... DOHA , April 27, 2015 ... medical information products and services, and Qatar University Research Office ... 2015 Scopus Awards. The awards ceremony, held last ... Doha , was attended by more than 40 guests ... Scopus awards were presented by Professor Sheikha Abdulla Al-Misnad ...
Breaking Biology Technology:New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2SynGen Inc. Expands Its Management Team 2Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 2Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5
... 5 Dynamic Alert,Limited (OTC Bulletin Board: DYMC) ... its target markets for its pharmaceutical product line-up. ... for enhancing rapid onset,through oromucosal absorption, topical applications, ... internal use. Some products will have,specific uses, while ...
... Dec. 5 Early clinical experience with the FDA,cleared ... of ultrasound guided cryoablation to completely eradicate,small, unifocal Invasive ... study was presented at the 94th Scientific Assembly and ... November 29 -,December 5, 2008. , ...
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext ... Agreement with the http://www.senesco.com ("Harris Moran") has ... recently announced corporate restructuring. , ... parent company, Limagrain, restructured its vegetable seed operations and ...
Cached Biology Technology:Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 2Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 3Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... of Pennsylvania School of Medicine & School of Engineering ... deliver drugs to tumors. By using a cylindrical-shaped carrier ... paclitaxel to an animal model of lung cancer ten ... findings have implications for drug delivery as well as ...
... vitamin was named, what is known about them ... public health, says Irwin Rosenberg, MD, University Professor, ... at the Jean Mayer USDA Human Nutrition Research ... on his presentation at the National Institutes of ...
... was published in an advance online edition of the Proceedings ... April 9, 2007. , The study provides new evidence that ... is activated by the protein SGT1, which also activates Resistance ... pathogens. The study also confirms structural similarities between the Nod1 ...
Cached Biology News:Penn researchers show how nanocylinders deliver medicine better than nanospheres 2Vitamins: Science doesn't always match policy 2Scripps research study shows humans and plants share common regulatory pathway 2Scripps research study shows humans and plants share common regulatory pathway 3
... service is for when you need to make ... their transformation efficiency. Our services for preparing competent ... applications. MCLab's custom competent cell service offers: ... Fast turnaround Quality control ...
... WR Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents can be used, such ... ... ... ...
Growth Medium / Media...
... Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of determination; triple-point ... ... ... ...
Biology Products: